Cyproterone

Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names

Europe

Austria: Andro-Diane, Androcur, MaskuPel; Belgium: Androcur, Cyproplex; Bulgaria: Androcur, Cyproterone; Czech Republic: Androcur, Cyproplex, Cyproteronacetat, Cysaxal; Denmark: Androcur; Estonia: Androcur; Finland: Androcur; France: Androcur, Cyproterone; Germany: Androcur, Cyproteron, Virilit; Greece: Androcur, Cyproterone; Hungary: Androcur, Cysaxal; Ireland: Androcur; Italy: Androcur; Latvia: Androcur, Cyproplex; Lithuania: Androcur, Cyproplex; Netherlands: Androcur, Cyproteronacetaat, Cysaxal; Poland: Androcur; Portugal: Androcur, Ciproterona; Romania: Androcur; Slovakia: Androcur, Cyproplex; Slovenia: Androcur; Spain: Androcur; Sweden: Androcur; UK: Androcur, Cyprostat, Cyproterone.

North America

Canada: Androcur, Cyproterone.

Latin America

Argentina: Androcur, Androstat, Asoteron, Ceprater, Ciclamil, Ciprofarma, Ciproplex, Ciproterona, Kebirterona, Omnigeriat, Purfilx; Brazil: Andelux, Androcur, Androneo, Androsteron, Cetoteron, Ciprostat, Tess; Mexico: Androcur, Bagopront, Neoproxil.

Drug combinations

Cyproterone and Estradiol

Cyproterone and Ethinyl Estradiol

Chemistry

Cyproterone Acetate: C~24~H~29~ClO~4~. Mw: 416.94. (1) 3’H-Cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1β,2β)-; (2) 6-Chloro-1β,2β-dihydro-17-hydroxy-3’H-cyclopropa[1,2]-pregna-1,4,6-triene-3,20-dione acetate. CAS-427-51-0; CAS-2098-66-0 (cyproterone)(1965).

Pharmacologic Category

Hormones and Synthetic Substitutes; Antiandrogens. (ATC-Code: G03HA01).

Mechanism of action

Cyproterone is a steroidal compound with antiandrogenic, antigonadotropic, and progestin-like activity.

Therapeutic use

Palliative treatment of advanced prostate carcinoma.

Pregnancy and lactiation implications

Not indicated for use in women.

Unlabeled use

Contraindications

Hypersensitivity to cyproterone or any component of the formulation. Active liver disease or hepatic dysfunction. Renal impairment.

Warnings and precautions

Has been associated with hepatic toxicity (jaundice, hepatitis, hepatic failure; toxicity develops after several months of therapy). May increase HDL-C and decrease LDL-C. Triglycerides may also be increased (use with caution in familial defects of lipoprotein metabolism). May increase the risk of thromboembolism. Use with caution in conditions which may be aggravated by fluid retention, or cardiovascular disease. Has been associated with an increased incidence of depression. May cause alterations in glucose metabolism (caution if diabetes or impaired glucose tolerance).

Information

Legal

Legal Notice
Privacy Policy
Cookie Policy

Contact

Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart